12/18
07:02 pm
anvs
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients [Yahoo! Finance]
Neutral
Report
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients [Yahoo! Finance]
12/18
04:35 pm
anvs
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Low
Report
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
12/16
08:00 am
anvs
Annovis to Host Corporate Update Webinar on January 28, 2026
Medium
Report
Annovis to Host Corporate Update Webinar on January 28, 2026
12/3
08:00 am
anvs
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Medium
Report
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
11/24
08:00 am
anvs
Annovis Announces Two Presentations at the CTAD 2025 Conference
High
Report
Annovis Announces Two Presentations at the CTAD 2025 Conference
11/18
08:00 am
anvs
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
High
Report
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
11/17
08:00 am
anvs
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
High
Report
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
11/12
08:00 am
anvs
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
High
Report
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
11/6
08:00 am
anvs
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
Medium
Report
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
10/27
08:00 am
anvs
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
High
Report
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules